Beta-Blocker Interruption or Continuation after Myocardial Infarction
Inserm · Université de Montpellier · +6 more institutions
Abstract
The appropriate duration of treatment with beta-blocker drugs after a myocardial infarction is unknown. Data are needed on the safety and efficacy of the interruption of long-term beta-blocker treatment to reduce side effects and improve quality of life in patients with a history of uncomplicated myocardial infarction.
In a multicenter, open label, randomized, noninferiority trial conducted at 49 sites in France, we randomly assigned patients with a history of myocardial infarction, in a 1:1 ratio, to interruption or continuation of beta-blocker treatment. All the patients had a left ventricular ejection fraction of at least 40% while receiving long-term beta-blocker treatment and had no history of a cardiovascular event in the previous 6 months. The primary end point was a composite of death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for cardiovascular reasons at the longest follow-up (minimum, 1 year), according to an analysis of noninferiority (defined as a between-group difference of
Citation impact
- FWCI
- 49.36
- Percentile
- 100%
- References
- 17
Authors
36- JSJohanne SilvainCorresponding
Inserm, Université de Montpellier, Université Paris Cité, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Hôpital Bichat-Claude-Bernard, Université Paris 1 Panthéon-Sorbonne
- GCGuillaume Cayla
Inserm, Université de Montpellier, Université Paris Cité, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Hôpital Bichat-Claude-Bernard, Université Paris 1 Panthéon-Sorbonne
- ÉFÉmile Ferrari
Inserm, Université de Montpellier, Université Paris Cité, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Hôpital Bichat-Claude-Bernard, Université Paris 1 Panthéon-Sorbonne
- GRGrégoire Rangé
Inserm, Université de Montpellier, Université Paris Cité, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Hôpital Bichat-Claude-Bernard, Université Paris 1 Panthéon-Sorbonne
- ÉPÉtienne Puymirat
Inserm, Université de Montpellier, Université Paris Cité, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Hôpital Bichat-Claude-Bernard, Université Paris 1 Panthéon-Sorbonne
Topics & keywords
- Myocardial infarction
- Continuation
- Cardiology
- Beta blocker
- Internal medicine
- Medicine
- BETA (programming language)
- Computer science